No room for 'biased' patients and doctors in Germany's AMNOG system
This article was originally published in Scrip
Patient organizations and medical societies are not impartial enough and lack the expertise to have any greater involvement in Germany's AMNOG pricing and reimbursement system, said Josef Hecken, head of the G-BA, the committee in charge of the AMNOG process.
You may also be interested in...
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.